{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:03:16Z","timestamp":1790053396555,"version":"4.0.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>A 49-year-old woman with cT3N1M0 stage IIIA HER2-positive invasive breast cancer is described in this retrospective case report. After six cycles of TCHP neoadjuvant chemotherapy, breast MRI confirmed that the primary lesion and axillary lymph nodes achieved radiological complete response. However, newly enlarged lymph nodes in levels II and III of the left neck were detected by neck ultrasound and contrast-enhanced CT. Subsequent 18F-FAPI-04 PET\/CT revealed significantly elevated tracer uptake in these cervical lymph nodes, with a maximum standardized uptake value (SUVmax) of 18.2, which was highly suspicious for metastasis. Ultrasound-guided core needle biopsy and postoperative histopathological examination finally confirmed that these cervical lymph nodes were benign reactive lymphoid hyperplasia with focal necrosis and inflammatory cell infiltration, and the patient achieved pathological complete response in both breast and axillary regions without any lymph node metastasis. This case reveals that despite the high sensitivity of FAPI PET\/CT in detecting malignant tumor lesions, benign post-treatment inflammatory processes can induce significant FAP upregulation, leading to typical false-positive results. Clinical interpretation of FAPI PET\/CT findings must be closely integrated with the patient\u2019s treatment history and multimodality examinations, and histopathology should remain the gold standard for definitive lesion characterization to avoid unnecessary misdiagnosis and overtreatment.<\/jats:p>","DOI":"10.3389\/fonc.2026.1938265","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:22:19Z","timestamp":1790050939000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["False-positive cervical lymph nodes on FAPI PET\/CT after neoadjuvant chemotherapy for breast cancer: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Ying","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, General Hospital of Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, General Hospital of Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, General Hospital of Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiqin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, General Hospital of Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, General Hospital of Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"17S","DOI":"10.2967\/jnumed.115.157859","article-title":"18F-FDG PET\/CT for staging and restaging of breast cancer","volume":"57","author":"Groheux","year":"2016","journal-title":"J Nucl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: Tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J Nucl Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1148\/radiol.2021204677","article-title":"Simultaneous FAPI PET\/MRI targeting the fibroblast-activation protein for breast cancer","volume":"302","author":"Backhaus","year":"2022","journal-title":"Radiology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262808","article-title":"Pitfalls and common findings in 68Ga-FAPI PET: a pictorial analysis","volume":"63","author":"Kessler","year":"2022","journal-title":"J Nucl Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2025.02.005","article-title":"The role of infraclavicular and supraclavicular lymph nodes in breast cancer patients receiving neoadjuvant chemotherapy: implications for regional lymph node classification","volume":"5","author":"Chen","year":"2025","journal-title":"J Natl Cancer Cent"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2023.108292","article-title":"Breast cancer dermal lymphatic invasion recurrence and contralateral axillary lymph nodes metastasis after complete response to neoadjuvant therapy: a case report","volume":"106","author":"Takemoto","year":"2023","journal-title":"Int J Surg Case Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"21948","DOI":"10.1038\/s41598-025-04588-y","article-title":"Prediction of contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma based on radiomics","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2174\/156652412803833607","article-title":"Fibroblast activation protein in remodeling tissues","volume":"12","author":"Jacob","year":"2012","journal-title":"Curr Mol Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000004751","article-title":"68Ga-FAPI-04 PET\/CT in selected breast cancer patients with low FDG affinity: a head-to-head comparative study","volume":"48","author":"Al\u00e7\u0131n","year":"2023","journal-title":"Clin Nucl Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1053\/j.semnuclmed.2023.02.001","article-title":"FAPI-avid nonmalignant PET\/CT findings: an expedited systematic review","volume":"53","author":"Bentestuen","year":"2023","journal-title":"Semin Nucl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.220749","article-title":"FAPI PET: Fibroblast activation protein inhibitor use in oncologic and nononcologic disease","volume":"306","author":"Mori","year":"2023","journal-title":"Radiology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13081450","article-title":"In vivo fibroblast activation of systemic sarcoidosis: A 68Ga-FAPI-04 PET\/CT imaging study","volume":"13","author":"Wang","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.633534","article-title":"Case report: Transformation from cold to hot tumor in a case of NSCLC neoadjuvant immunochemotherapy pseudoprogression","volume":"12","author":"Jia","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1938265\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:22:21Z","timestamp":1790050941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1938265\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":19,"alternative-id":["10.3389\/fonc.2026.1938265"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1938265","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1938265"}}